Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
Portfolio Pulse from Vandana Singh
The FDA has lifted the partial clinical hold on Arcellx Inc's iMMagine-1 Phase 2 Clinical Program. Analysts from Needham and William Blair remain optimistic about the long-term therapeutic potential of Arcellx's CART-ddBCMA, despite a delay in the timeline for interim data and regulatory submissions. ACLX shares were up 5.8% at $35.65 on the last check Tuesday.
August 15, 2023 | 6:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's lifting of the clinical hold on Arcellx's iMMagine-1 Phase 2 Clinical Program and analysts' continued optimism about the long-term potential of CART-ddBCMA are positive for ACLX. The stock was up 5.8% on the last check Tuesday.
The FDA's decision to lift the clinical hold on Arcellx's iMMagine-1 Phase 2 Clinical Program removes a significant hurdle for the company. This, combined with analysts' continued optimism about the long-term potential of CART-ddBCMA, is likely to boost investor confidence in ACLX, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100